Overview

Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C

Status:
Active, not recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

Study SPC3649-207E is designed as an extension study to the prior protocol to provide additional long-term safety and efficacy information for subjects participating in Study SPC3649-207.

Phase:

Phase 2

Details

Lead Sponsor:

Santaris Pharma A/S

Treatments:

Interferon-alpha
Interferons
Ribavirin